Condition

EGFR Mutation Positive Advanced Non Small Cell Lung Cancer

ClinicalTrials.gov condition label

How to interpret these research links

Connected source records

This is the original ClinicalTrials.gov condition label, found in 3 distinct published trials. It is kept separate from a MONDO disease identifier until a specific normalization is supported. Related interventions are co-recorded in studies; they are not medical recommendations.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Clinical trials3

Recruiting1

Common interventions6

Lead sponsors shown3

Clinical trials

3 shown

ORIENT-31 Regimen in Combination With SBRT for EGFR-mutant Metastatic NSCLC After First-line Third-generation EGFR-TKIsNCT06775743 · 2025-01-15

RECRUITING

A Clinical Study on the Efficacy and Safety of the Combination of Limertinib and Bevacizumab Versus Limertinib as First-line Treatment for NSCLC.NCT06982924 · 2025-06-30

NOT_YET_RECRUITING

Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors, AZD3759 or AZD9291, in Patients Who Have Advanced Non-Small Cell Lung CancerNCT02228369 · 2014-11-05

COMPLETED

Common interventions

AZD3759DRUG1 AZD9291DRUG1 LimertinibDRUG1 Limertinib+bevacizumabDRUG1 ORIENT-31 regimenDRUG1 SBRTRADIATION1

Leading sponsors

AstraZeneca 1 Fudan University 1 Shanghai Chest Hospital 1

Trial status mix

COMPLETED1

NOT_YET_RECRUITING1

RECRUITING1

Phase mix

PHASE22

PHASE11

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.